"Designing Growth Strategies is in our DNA"

Stomach Cancer/Gastric Cancer Treatment Market Size, Share & Industry Analysis, By Drug Type (Programmed Cell Death Protein 1 (PD-1) Inhibitors, Human Epidermal Growth Factor Receptor (HER2) Antagonists, and Others), By Disease Indication (Gastric Adenocarcinoma, Gastrointestinal Stromal Tumor (GIST)), By Route of Administration (Oral and Parenteral) By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others) and Regional Forecast, 2019-2026

Region : Global | Format: PDF | Report ID: FBI102094

 

KEY MARKET INSIGHTS

Play Audio Listen to Audio Version

The global stomach cancer/gastric cancer treatment market size stood at USD 2.61 billion in 2018 and is projected to reach USD 8.20 billion by 2026, exhibiting a CAGR of 15.3% during the forecast period.

COVID-19 Cover

We are in process of revamping Stomach-Gastric- Cancer- Treatment Market with respect to COVID-19 Impact.

Request Sample

Stomach cancer is the fifth most common cancer in the world. According to Cancer Research U.K., 6,697 gastric carcinoma cases are diagnosed each year. Stomach cancers are classified into three types. Gastric Adenocarcinoma is the most common type of stomach cancer and accounts for 90%-95% of stomach cancer cases. Gastrointestinal Stromal Tumor (GIST) and Gastric Neuroendocrine Tumors (gNET) are rare in nature. Rising incidence of cancer cases and limited drugs as first-line treatment are the major factors that have encouraged many pharmaceutical giants to conduct research for the development of novel drugs.


This has also paved the way for many significant strategic collaborations between pharmaceutical companies. For example, in March 2019, AstraZeneca entered into a development and commercialization agreement with Daiichi Sankyo, Inc., for trastuzumab deruxtecan, an antibody-drug conjugate under investigation for gastric carcinoma. As a result, the gastric cancer drugs market is receiving a lot a traction. In addition to this, active government support is also expected to boost the market.


Request a Free sample to learn more about this report.


Programmed Cell Death Protein 1 (PD-1) inhibitors are considered to be the rising star in the market. Owing to the positive and effective results of PD-1 blocking antibody, they are actively being adopted for the treatment of gastric carcinoma. Apart from this, the launch of biosimilars of trastuzumab and the rapid adoption of biosimilars in oncology is booming the market for gastric cancer treatment.


MARKET DRIVERS


“Rising Prevalence of Gastric Cancer to Fuel the Market”


Stomach cancer is emerging as a leading cause of death across the world. According to WHO, the incident cases of stomach cancer are estimated to increase from 1.03 million in 2018 to 1.24 million by 2025. This increasing prevalence of gastric carcinoma is expected to boost the demand for gastric cancer treatment during the forecast period and become one of the leading stomach cancer treatment market trends.


Furthermore, the rapid adoption of advanced diagnostic tools for the early detection of stomach cancer is raising the patient population. This is anticipated to favor the stomach cancer drugs market growth during the forecast period


“Presence of Potential Pipeline Candidates to Boost the Market”


Many pharmaceutical companies are actively investing in the research and development of novel drugs for the treatment of stomach cancer. Many potential candidates are in their end stages of development and are projected to give a tremendous boost to the market after their launch. For example, in November 2019, Pfizer and EMD Serono, Inc. announced positive results from their phase III clinical study on avelumab for the treatment of advanced gastric cancer. In addition to this, various biosimilars of trastuzumab are either entering the market or are under development. This, coupled with an increasing preference for biosimilars for cancer treatment, is poised to surge the market.


On the contrary, high cost of the drugs and stomach cancer treatment side effects are the major factors that are expected to hinder the stomach cancer therapeutics market.


SEGMENTATION


By Drug Type Analysis


“PD-1 Inhibitors Segment to Witness Remarkable Growth”


On the basis of drug type, the market can be segmented into Programmed Cell Death Protein 1 (PD-1) inhibitors, Human Epidermal Growth Factor Receptor (HER2) antagonists, Vascular Endothelial Growth Factor Receptor (VEGFR) antagonists, and others. The PD-1 inhibitors segment is estimated to account for the maximum portion of the market owing to the increased research on PD-1 inhibitors and new product approvals. In September 2017, Keytruda received FDA approval for the treatment of stomach cancer. This is anticipated to accelerate the growth of the PD-1 inhibitors segment.


To know how our report can help streamline your business, Speak to Analyst


The presence of potential pipeline candidates and the green signal from the government for biosimilars of trastuzumab are expected to drive the growth of the HER2 antagonists segment during 2018-2026. The VEGFR antagonists segment is projected to expand owing to the rising prevalence of stomach cancer, new product launches, and favorable health reimbursement. The prominent use of Lonsurf, fluorouracil, capecitabine, and other chemo drugs as the first line of treatment for gastric carcinoma are the primary reasons responsible for the growth of the others segment. Stomach cancer treatment chemotherapy is a widely preferred option in developing countries which is positively impacting the others segment.


By Disease Indication Analysis


“Gastric Adenocarcinoma Segment to Dominate the Market”


Based on disease indication, the market can be segmented into gastric adenocarcinoma, gastrointestinal stromal tumors (GIST), and gastric Neuroendocrine Tumors (gNET). The gastric adenocarcinoma segment is likely to dominate the market throughout the forecast period owing to the rising prevalence of gastric adenocarcinoma and rapid adoption of targeted therapy and immuno-checkpoint inhibitors for the treatment of gastric adenocarcinoma. Potential pipeline candidates and the growing trend of research collaborations are expected to favor the expansion of gastrointestinal stromal tumors and gastric neuroendocrine tumors segments.


By Route of Administration Analysis


“Parenteral Segment to Register the Maximum CAGR”


On the basis of route of administration, the market can be segmented into oral and parenteral. Favorable reimbursement and the presence of more intravenous drugs for treating stomach cancer are poised to surge the parenteral segment. On the other hand, convenience with oral drugs and increasing sales of Lonsurf and Afinitor are likely to propel the demand for oral drugs.


By Distribution Channel Analysis


“Strong Government Support to Favor the Hospital Pharmacy Segment”


In terms of distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. Strong government support for cancer treatment through establishment of government-aided hospitals and pharmacy and favorable reimbursement are the major factors attributable to the expansion of the hospital pharmacy segment. The retail pharmacy segment is anticipated to grow owing to the increasing number of cancer treatment centers, rising prevalence of stomach cancer, and increasing patient pool. The online pharmacy segment is projected to witness remarkable growth during the forecast period owing to the rapid adoption of online stores for purchasing drugs and rising focus of pharmaceutical companies to strengthen their distribution networks.                                   


REGIONAL ANALYSIS


Asia Pacific, with a revenue of USD 1.01 billion in 2018, accounted for the major portion of the gastric cancer treatment market share. The region is estimated to dominate the market throughout the forecast period. Primary factors attributed to the dominant share of Asia Pacific are the rising cases of gastric cancer especially in Japan, China and India and the rapid adoption of PD-1 inhibitors. According to WHO, the number of incident cases for stomach cancer in Japan and China was 115,546 and 456,124 respectively in 2018. This rising incidence along with new product launches are anticipated to augment the market for gastric cancer treatment in Asia. 


Asia Pacific Stomach Cancer/Gastric Cancer Treatment Market Size, 2018

To get more information on the regional analysis of this market, Request a Free sample


Strategic collaborations between major pharmaceutical companies, increased R&D spending, and rapid adoption of targeted therapy and immunotherapy are expected to foster the demand for gastric carcinoma drugs in North America. According to the American Society of Clinical Oncology, 27,510 people are estimated to be diagnosed with stomach cancer in 2019 in the U.S. This is likely to fuel the market for stomach cancer drugs in North America.


In Europe, the market is estimated to flourish owing to new product launches, favorable health reimbursement, and active government support. In April 2019, Boehringer Ingelheim, a Germany-based company, collaborated with PureTech Health, to help the company to apply PureTech’s lymphatic targeting platform to the company immuno-oncology candidate for gastric cancer. As a result, the drug can be administrated directly to the gut lymphatics. The expected launch of such drugs that can be directly administered to the site is anticipated to fuel the market in Europe. In Latin America and the Middle East & Africa, the demand for gastric carcinoma treatment is projected to boost owing to the improving health infrastructure, unmet patient needs, and the launch of new products.


INDUSTRY KEY PLAYERS


“Merck & Co., Inc. and F. Hoffmann-La Roche Ltd. to Lead the Market”


In terms of stomach cancer treatment market revenue, Merck & Co., Inc. and F. Hoffmann-La Roche Ltd. accounted for the leading position. Approval of Keytruda for gastric cancer in 2017 in the U.S. and Japan increased demand for the drug and this rendered Merck with the maximum share of the market in 2018. On the other hand, Roche accounted for the second position in the market owing to the rising demand for Roche’s blockbuster drug Herceptin for gastric cancer and also prominent use of Xeloda for chemo treatment.


List Of Key Companies Covered:



  • Ipsen Pharma

  • Merck & Co., Inc.

  • Bristol-Myers Squibb Company

  • Eli Lilly and Company

  • F. Hoffmann-La Roche Ltd

  • Novartis AG

  • Bayer AG

  • Celltrion Inc.

  • TAIHO PHARMACEUTICAL CO., LTD.

  • Jiangsu Hengrui Medicine Co., Ltd.


REPORT COVERAGE


Stomach cancer is among the most commonly occurring cancer in the world especially in Asia. Owing to its rising prevalence and increasing patient pool, many pharmaceutical companies are making significant investments in the development of novel therapies. Presence of promising pipeline candidates and rapid uptake of targeted and immune therapy is boosting the market.


To gain extensive insights into the market, Request for Customization


The gastric cancer treatment market report offers an in-depth analysis of the market. It further provides details on the prevalence of stomach cancer for key countries, regulatory and reimbursement scenario for key countries, new product launches, and key industry developments such as mergers, acquisitions, and partnerships. Information on drivers, opportunities, threats, and restraints of the market can further help stakeholders to gain valuable insights into the market. The report offers a detailed competitive landscape by presenting information on key players, along with their strategies, in the market.


Report Scope & Segmentation














































 ATTRIBUTE



 DETAILS



Study Period



  2015-2026



Base Year



  2018



Forecast Period



  2019-2026



Historical Period



  2015-2017



Unit



  Value (USD million)



Segmentation



By Drug Type



  • Programmed Cell Death Protein 1 (PD-1) Inhibitors

  • Human Epidermal Growth Factor Receptor (HER2) Antagonists

  • Vascular Endothelial Growth Factor Receptor (VEGFR) Antagonists

  • Others



By Disease Indication



  • Gastric Adenocarcinoma

  • Gastrointestinal Stromal Tumor (GIST)

  • Gastric Neuroendocrine Tumors (gNET)



By Route of Administration



  • Oral

  • Parenteral



By Distribution Channel



  • Hospital Pharmacy

  • Retail Pharmacy

  • Online Pharmacy



By Geography



  • North America (U.S. and Canada)

  • Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)

  • Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia- Pacific)

  • Latin America (Brazil, Mexico, and Rest of Latin America)

  • Middle East and Africa ( South Africa, GCC, and Rest of Middle East & Africa)



INDUSTRY DEVELOPMENT:



  • November 2019: Pfizer and EMD Serono, Inc. announced positive results from their phase III clinical study on avelumab for the treatment of advanced gastric cancer.

  • April 2019: Boehringer Ingelheim, a Germany-based company, collaborated with PureTech Health, which will help the company to apply PureTech’s lymphatic targeting platform to the company’s immuno-oncology candidate for gastric cancer. As a result, the drug can be administrated directly to the gut lymphatics.

  • March 2019: AstraZeneca entered into a development and commercialization agreement with Daiichi Sankyo, Inc., for trastuzumab deruxtecan, an antibody-drug conjugate under investigation for gastric carcinoma.

  • September 2017: Keytruda, a PD-1 inhibitor developed by Merck, received FDA approval for the treatment of stomach cancer.


Frequently Asked Questions

The value of the global stomach cancer/gastric cancer treatment market was USD 2.61 billion in 2018.

Fortune Business Insights says that the stomach cancer/gastric cancer treatment market is projected to reach USD 8.20 billion by 2026.

The value of Asia Pacific stomach cancer/gastric cancer treatment market was USD 1.01 billion in 2018.

The stomach cancer/gastric cancer treatment market is projected to grow at a CAGR of 15.3% during the forecast period (2019-2026).

Programmed Cell Death Protein 1 (PD-1) inhibitors segment is the leading segment in this market during the forecast period.

Rising prevalence of stomach cancer is the key factor driving the stomach cancer/gastric cancer treatment market.

Merck & Co., Inc. and F. Hoffmann-La Roche Ltd are the top players in the market.

Asia-Pacific is expected to hold the highest market share in the market.

Adoption of Programmed Cell Death Protein 1 (PD-1) inhibitors and research on developing biosimilars of trastuzumab are the key trends of the stomach cancer/gastric cancer treatment market.

Seeking Comprehensive Intelligence on Different Markets?
Get in Touch with Our Experts

Speak to an Expert
Stomach-Gastric- Cancer- Treatment Market Size, Share and Global Industry Trend Forecast till 2026
  • Feb, 2020
  • 2018
  • 2015-2017
  • 130

    CHOOSE LICENSE TYPE

  • 4850
    6850
    8850

Personalize this Research

  • Granular Research on Specified Regions or Segments
  • Companies Profiled based on User Requirement
  • Broader Insights Pertaining to a Specific Segment or Region
  • Breaking Down Competitive Landscape as per Your Requirement
  • Other Specific Requirement on Customization
Request Customization Banner

Client Testimonials

“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”

- One of the Leading Food Companies in Germany

“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”

- Intuitive Surgical

“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”

- Major Food Company in Japan

“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”

- Ziering Medical

“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”

- Major Manufacturer of Precision Machine Parts in India

“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”

- Hewlett-Packard

“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”

- Global Management Consulting Firm

“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”

- UK-based Start-up in the Medical Devices Sector

“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”

- One of the Largest Companies in the Defence Industry
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . More info.
X